onconcept®
ONConcept® is a strategic partnership of Bluepharma, Helm AG, and Welding that develops, manufactures, and licenses complex, highly potent generic pharmaceuticals — primarily oncology drugs — through long-term multi-molecule alliances with global pharmaceutical companies.
- Company typePrivate
- Founded2019
- HeadquartersCoimbra, Portugal
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What onconcept® does
ONConcept® is a strategic partnership formed in 2019 by three independent, certified European pharmaceutical companies — Bluepharma (Portugal), Helm AG (Germany), and Welding GmbH & Co. KG (Germany) — to develop, manufacture, and supply complex, highly potent pharmaceutical products, principally generic oncology drugs and other difficult-to-make therapeutics. The partnership operates a dedicated EU-GMP manufacturing site in Eiras, Coimbra, Portugal, purpose-built for oral solid high-potency dosage forms with a €30 million capital investment and approximately 100 highly qualified staff, with the site successfully inspected by the USFDA on six occasions and by multiple other national regulatory authorities.
The portfolio comprises more than 20 generic molecules including blockbusters such as ibrutinib, palbociclib, cabozantinib, nilotinib, olaparib, and enzalutamide, spanning oncology, hematology, immunology, and antivirals. ONConcept pairs these assets with proprietary formulation work — notably a nanoenzalutamide tablet developed with Nanoform — and offers an end-to-end service stack covering IP support, API sourcing, FDF development and manufacturing, clinical development, and regulatory support. The company targets the wave of patent expirations (2020–2024) affecting highly potent anticancer molecules with annual sales exceeding $26 billion, with planned launches including Nilotinib in 2026 and nanoenzalutamide potentially as early as 2028.
Commercially, ONConcept serves multinational and local pharmaceutical companies through long-term, multi-molecule strategic alliances rather than one-off product licenses, leveraging the complementary strengths of its three founding partners (Bluepharma's CDMO capabilities and EU-GMP manufacturing, Helm's scientific and regulatory expertise with 120+ years of corporate history, and Welding's API sourcing and project leadership) to position itself as an integrated European hub serving global markets including the US, South America, and Asia-Pacific.
onconcept® firmographics
Firmographics- Name
- onconcept®
- Legal name
- ONConcept®
- Website
- https://onconceptpharma.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Short description
- ONConcept® is a strategic partnership of Bluepharma, Helm AG, and Welding that develops, manufactures, and licenses complex, highly potent generic pharmaceuticals — primarily oncology drugs — through long-term multi-molecule alliances with global pharmaceutical companies.
- Ownership category
- akta.pro rank
onconcept® industry classification
Industry- Product category
- Generic Oncology Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
- akta.pro secondary industries
- Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where onconcept® is headquartered
LocationHeadquarters
- HQ city
- Coimbra
- HQ country
- Portugal
- HQ region
- Europe
Offices4 records
Markets served
onconcept® business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- Pharmaceutical Licensing: Licensing of developed generic pharmaceutical products (highly potent molecules) to marketing partners worldwide. Products include oncology drugs and other complex therapeutics at various stages of regulatory approval.
- Contract Development and Manufacturing (CDMO): Bluepharma operates as a CDMO with full capabilities to develop medicines from concept through commercial manufacturing. Services include FDF development, manufacturing, supply chain management, clinical development, regulatory support, and IP services.
- Product Supply: Supply of manufactured highly potent pharmaceutical products to pharmaceutical companies under long-term strategic alliances.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
onconcept® product offering
Product offeringCore offering
ONConcept® is a strategic partnership that develops, manufactures, and licenses generic versions of oncology and other highly potent pharmaceutical products (oral solid dosage forms) for marketing partners worldwide. The partnership operates a €30 million EU-GMP approved manufacturing facility in Portugal and provides integrated CDMO services across the full pharmaceutical value chain, including IP support, API sourcing, FDF development/manufacturing/supply chain, clinical development, and regulatory support for more than 20 molecules.
Product overview
ONConcept® is a strategic partnership among three European pharmaceutical companies (Bluepharma, Helm Pharma, and Welding) providing integrated CDMO services for complex, differentiated, and highly potent pharmaceutical products. The portfolio consists of 20+ generic pharmaceutical products including oral solid dosages (tablets and capsules) spanning oncology (abiraterone acetate,apalutamide, cabozantinib, enzalutamide, lenvatinib, nilotinib, olaparib, palbociclib, pazopanib, pomalidomide, ribociclib, ruxolitinib, sunitinib, venetoclax), hematology (eltrombopag, avatrombopag), immunology (fingolimod, tofacitinib standard and extended-release), with partner Nanoform for nano-formulation technology. The services span the full value chain: IP support, API sourcing, FDF development and manufacturing, clinical development, and regulatory support. EU-based manufacturing facility in Portugal with GMP certifications.
Differentiator
Problem solved
Functional benefit
Products and services
- Abiraterone Acetate Generic version of Zytiga® (250mg, 500mg tablets) for the treatment of prostate cancer, supplied for licensing and distribution to pharmaceutical partners.
- Apalutamide Generic version of Erleada® (60mg, 240mg tablets) for the treatment of prostate cancer, supplied for licensing and distribution to pharmaceutical partners.
- Avatrombopag Generic version of Doptelet® (20mg tablets) for the treatment of thrombocytopenia, supplied for licensing and distribution to pharmaceutical partners.
- Cabozantinib Generic version of Cabometyx® (20mg, 40mg, 60mg tablets) for renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer, supplied for licensing and distribution to pharmaceutical partners.
- Eltrombopag Generic version of Revolade®/Promacta® (25/50/75 mg tablets) for thrombocytopenia and severe aplastic anemia, supplied for licensing and distribution to pharmaceutical partners.
- Enzalutamide
Quantifiable outcome
- Portfolio of 20+ molecules including top sellers like ibrutinib (Imbruvica®) and palbociclib (Ibrance®)
- +2 more outcomes
Companies that use onconcept®
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
onconcept® technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
onconcept® partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- BluepharmacoreBluepharma is a Portuguese pharmaceutical company operating as a CDMO with all capabilities needed to develop medicines from concept through commercial manufacturing. Bluepharma brings EU-GMP approved manufacturing capabilities, global regulatory experience, and the manufacturing facility base for ONConcept. As a founding partner, Bluepharma provides development expertise, regulatory filing capabilities, and the production infrastructure.
- Helm Pharma (Helm AG)coreHelm is a family-owned, 120-year-old German pharmaceutical company with strong track record collaborating with international partners on generic pharmaceutical development. Helm brings scientific, regulatory, and quality expertise, experience coordinating different stakeholders, and special expertise in identifying opportunities for difficult and complex molecules. As a founding partner, Helm handles active pharmaceutical ingredient (API) expertise and regulatory coordination.
- Welding (Welding GmbH & Co. KG)coreWelding is a German pharmaceutical company based in Hamburg, with history dating back to 1955 involved in API supply. Welding brings expertise in identifying and handling ingredients, connecting API suppliers to finished dosage form manufacturers. The company has excellent reputation for leading projects from start to finish, with experience in markets including India, China, and the US. As a founding partner, Welding provides API sourcing network and project leadership.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
onconcept® competitors and assessment
Company assessmentMarket position
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
onconcept® social profiles
Digital presenceonconcept® compliance and trust
Trust signalCompliance7 records
onconcept® financial estimates
Financial estimateRevenue estimate
Valuation estimate
onconcept® leadership team
Management profileNumber of profiles
Profiles4 records
onconcept® funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
onconcept® M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about onconcept®
What does onconcept® do?
ONConcept® is a strategic partnership that develops, manufactures, and licenses generic versions of oncology and other highly potent pharmaceutical products (oral solid dosage forms) for marketing partners worldwide. The partnership operates a €30 million EU-GMP approved manufacturing facility in Portugal and provides integrated CDMO services across the full pharmaceutical value chain, including IP support, API sourcing, FDF development/manufacturing/supply chain, clinical development, and regulatory support for more than 20 molecules.
Is onconcept® a public or private company?
onconcept® is a private company. It is classified as corporate owned and is currently operating.
When was onconcept® founded?
onconcept® was founded in 2019.
Where is onconcept® based?
onconcept® is headquartered in Coimbra, Portugal, in the Europe region.
How does onconcept® make money?
Three revenue lines are on record. Pharmaceutical Licensing is the primary driver. The others are contract Development and Manufacturing (CDMO) and product Supply.
Does onconcept® have an API?
No public API is recorded for onconcept®.
What industry is onconcept® in?
onconcept®'s product category is Generic Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 3254 and its SIC code is 2834.